Literature DB >> 24051266

Clusters of AMI risk factors and their association with left ventricular hypertrophy: a population-based study within the Skaraborg Project, Sweden.

Charlotte A Larsson1, Bledar Daka, Bo Gullberg, Lennart Råstam, Ulf Lindblad.   

Abstract

OBJECTIVES: Risk factors for acute myocardial infarction (AMI) are known to cluster and to be differently distributed in men and women. The aim of this study was to sex-specifically explore clusters of acknowledged AMI risk factors by factor analysis, and to study whether such clusters are associated with left ventricular hypertrophy (LVH), used as a subclinical measure of CHD.
METHODS: In 2001-2005, 2328 subjects (30-74 years) were randomly selected from two municipalities in Sweden (participation-rate 76%) and were assessed with regard to cardiovascular risk factors; 852 participants also had an echocardiographic examination performed.
RESULTS: Factor analysis identified three identical factors in men and women. WHR, HOMA-ir, systolic blood pressure, and ApoB/ApoA1 loaded significantly on the principal "metabolic factor", leisure-time physical activity and self-rated health loaded significantly on the "vitality factor", and smoking and alcohol consumption loaded significantly on the "addiction factor". The metabolic factor was associated with LVH in both men (P<0.001) and women (P<0.001), whereas the addiction factor was associated with LVH solely in men (P=0.002).
CONCLUSIONS: The consistent pattern in the clustering of acknowledged AMI risk factors suggests common underlying mechanisms in both men and women. However, whereas the metabolic factor was paramount in both men and women in the association with LVH, the addiction factor had an impact solely in men. As LVH often precedes AMI, a deeper understanding of risk factors for LVH, including consideration of the supposed sex differences, can be useful in order to explore prevention strategies for AMI.
© 2013.

Entities:  

Keywords:  AMI; CHD; Cardiovascular risk factors; Left ventricular hypertrophy; Population-based; Sex differences

Mesh:

Year:  2013        PMID: 24051266     DOI: 10.1016/j.ijcard.2013.08.047

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

1.  Systemic approach to identify serum microRNAs as potential biomarkers for acute myocardial infarction.

Authors:  An Hsu; Shu-Jen Chen; Yu-Sun Chang; Hua-Chien Chen; Pao-Hsien Chu
Journal:  Biomed Res Int       Date:  2014-05-12       Impact factor: 3.411

2.  Urinary chromium is associated with changes in leukocyte miRNA expression in obese subjects.

Authors:  L Dioni; S Sucato; V Motta; S Iodice; L Angelici; C Favero; T Cavalleri; L Vigna; B Albetti; S Fustinoni; P Bertazzi; A Pesatori; V Bollati
Journal:  Eur J Clin Nutr       Date:  2016-10-12       Impact factor: 4.016

3.  Longitudinal associations between sex hormone-binding globulin and insulin resistance.

Authors:  Kristin Ottarsdottir; Margareta Hellgren; David Bock; Anna G Nilsson; Bledar Daka
Journal:  Endocr Connect       Date:  2020-05       Impact factor: 3.335

4.  Circulating concentrations of endothelin-1 predict coronary heart disease in women but not in men: a longitudinal observational study in the Vara-Skövde Cohort.

Authors:  Bledar Daka; Josefin Olausson; Charlotte A Larsson; Margareta I Hellgren; Lennart Råstam; Per-Anders Jansson; Ulf Lindblad
Journal:  BMC Cardiovasc Disord       Date:  2015-11-14       Impact factor: 2.298

5.  Epidemiological and clinical implications of blood pressure measured in seated versus supine position.

Authors:  Ernest Privšek; Margareta Hellgren; Lennart Råstam; Ulf Lindblad; Bledar Daka
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

6.  Circulating endothelin-1 levels are positively associated with chronic kidney disease in women but not in men: a longitudinal study in the Vara-Skövde cohort.

Authors:  Margareta I Hellgren; Per-Anders Jansson; Hormoz Alayar; Ulf Lindblad; Bledar Daka
Journal:  BMC Nephrol       Date:  2021-10-02       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.